App-Quantinova.ai

The epidemiological profile of hospitalized acquired infections (HAIs) due to multidrug-resistant (MDR) pathogens in patients with hematological malignancies and solid neoplasms: Real World experience of a single cancer hospital.

Maria Kotsopoulou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Low rates of symptomatic venous thromboembolism in patients with gastrointestinal cancer: an Iranian study.

Mohammad Reza Mortazavizadeh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The effect of celebrity health disclosures on demand for health care: Trends in BRCA testing in 2013 and subsequent health services use.

Megan Roberts - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Perceptions of genetic testing among patients undergoing genetic counseling.

Katherine Clifton - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Comparative analysis of various targeted enrichment methodologies to identify actionable mutations in lung cancer.

Anup Madan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Germline mutational spectrum of Brazilian HBOC patients tested with hereditary cancer multigene panels.

Barbara Alemar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TP53

Landscape scanning of cancer gene panels: A report from the NIH Genetic Testing Registry (GTR).

Wendy S. Rubinstein - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Critical co-diagnostic or ancillary assessment: Germline testing for patients with somatic tumor profiling.

Edward Esplin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Outcome and follow-up of glioblastoma patients treated with bevacizumab based therapy in 2nd lign treatment.

Benjamin Auberger - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Bevacizumab

A revisit of the devastating outcome of leptomeningeal disease.

Ahmad Hatem Mattour - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A RT-qPCR Diagnostic System to Monitor Toca 511, a Cancer-selective Gene Therapy for the Treatment of Patients with Recurrent High-grade Glioma.

Erik Sudin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

vocimagene amiretrorepvec + Toca FC

Prognositc value of combining cancer metabolism related biomarkers in glioma patients.

Chengcheng Guo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Volumetric variation pre and postoperative in low-grade gliomas (LGG) assessed by mean tumor diameter (MTD).

Natalia Moreno Perez Fraile - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Optimal management of leptomeningeal carcinomatosis in breast cancer patients - a systematic review.

Shaan Dudani - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The role of systemic therapy after local treatment in breast cancer patients with first presentation of brain metastases recurrence.

Anna Niwinska - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Breast-GPA and type of treatment predictors of survival in brain metastasis patients.

Jenniffer Linares Aceituno - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Targeting PIWIL2-like (PL2L) proteins by a monoclonal antibody for immunotherapy of both solid and hematopoietic cancers.

Jian-Xin Gao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Chemotherapy (CT) of solid tumors and reactivation of latent viral infections (VI).

Tatyana A. Zykova - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Highly cytotoxic EGFR/CD16A TandAbs to recruit NK-cells to kill EGFR-expressing tumor cells.

Martin Treder - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The accuracy of carboplatin area under the curve (AUC) estimated by Calvert formula using Cockcroft-Gault formula and Thai eGFR in Thai cancer patients.

Kokiet Kangwantas - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Carboplatin

Filters

41730 Abstracts